- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07943702
Correlation Between Visual Reading and DOlab Software Quantitative Analysis of DaT-SPECT Images
Pre-market Clinical Investigation to Evaluate the Correlation Between Visual Interpretation and Quantitative Analysis Performed by DOlab Software - DaT-SPECT Workflow for the Identification of Neurological Disorders Related to Dopamine Transporter Dysfunction
The goal of this study is to find out whether the quantitative results of DOlab software (DaT-SPECT workflow) agree with the visual reading of brain scans performed by nuclear medicine physicians. The scans are 123I-ioflupane DaT-SPECT images of adults who were evaluated for dopamine transporter dysfunction, a condition seen in Parkinson's disease, other parkinsonian syndromes and dementia with Lewy bodies.
The main questions it aims to answer are:
- Do the visual scores given by expert readers (0 = normal to 3 = marked abnormality) correlate with the values calculated by the software?
- Does using the software report change or refine the readers' classification compared with visual reading alone?
- How usable do readers find the software?
The study uses existing scans of 120 patients collected between January 2015 and May 2025 at two Italian hospitals. No new tests or treatments are given to participants, and the software results are not used for their clinical care.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Dopamine transporter (DaT) SPECT with 123I-ioflupane is widely used to support the diagnosis of neurological disorders associated with nigrostriatal dopaminergic degeneration. Visual reading by trained physicians is the clinical standard, and semi-quantitative analysis is recommended by the EANM/SNMMI guidelines as an objective complement, especially in borderline cases.
DOlab software - DaT-SPECT workflow (Dorian Technologies; investigational, not CE-marked, class IIa) iteratively maps each scan to MNI space with adaptive volumes of interest for the right and left caudate, anterior putamen and posterior putamen, plus an occipital reference region. It computes four metrics: striatal binding ratio (SBR), Southampton SBR, Basal Ganglia V3 and Volume Fraction. The results are compared with a normative database derived from the Parkinson's Progression Markers Initiative (PPMI) and reported as z-scores.
This is a blinded, multicenter, retrospective investigation at two Italian sites. At each site, an independent reader selects 15 consecutive scans for each visual grade (0, 1, 2, 3), for a total of 120 scans. The images are pseudonymized and uploaded to a shared repository.
Phase 1: four independent readers (two per site), blinded to all clinical information except sex and age, visually score the randomized images (0-3) for the caudate, anterior putamen and posterior putamen of each hemisphere. In parallel, the software analyzes the same images, and the visual scores are correlated with the software metrics.
Phase 2: the images are re-randomized and re-coded, and the same readers perform a semi-quantitative assessment supported by the software report. Classifications from the two phases are then compared. Finally, the readers complete the System Usability Scale (SUS).
Sample size: 85 subjects are needed to detect a correlation of 0.30 (two-sided alpha 0.05, power 80%). 120 subjects are planned to allow for non-evaluable images.
Tipo di studio
Iscrizione (Stimato)
Contatti e Sedi
Contatto studio
- Nome: Paolo Bosco
- Numero di telefono: +39 320 070 6224
- Email: paolo.bosco@dorian-tech.com
Luoghi di studio
-
-
Tuscany
-
Prato, Tuscany, Italia, 59100
- Reclutamento
- Azienda USL Toscana Centro - Ospedale Santo Stefano
-
Investigatore principale:
- Stelvio Sestini, MD
-
-
Veneto
-
Padova, Veneto, Italia, 35128
- Reclutamento
- Azienda Ospedale Università Padova
-
Investigatore principale:
- Diego Cecchin, MD
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Adults referred for evaluation of nigrostriatal dopaminergic dysfunction who underwent 123I-ioflupane DaT-SPECT between January 2015 and May 2025 at Santo Stefano Hospital (Prato) or the University Hospital of Padua, Italy. At each center, 15 consecutive scans per visual grade (negative, mild, moderate and marked abnormality) are selected retrospectively.
Descrizione
Inclusion Criteria:
- Age 18 years or older.
- Referred for evaluation of nigrostriatal dopaminergic dysfunction to one of the participating centers between January 2015 and May 2025.
- Informed consent for data collection, or documentation that all reasonable efforts to obtain consent were made (Italian Privacy Code, art. 110).
- 123I-ioflupane SPECT images that:
- were acquired according to the PPMI imaging protocol;
- have a field of view covering the entire head, from the superior cortical regions to the lower cerebellum;
- followed the radiotracer manufacturer's acquisition timing and methods;
- were attenuation-corrected according to local standard procedures.
Exclusion Criteria:
- Age under 18 years.
- Use of drugs or substances that may significantly affect DaT binding (e.g., cocaine, amphetamines, CNS stimulants, opioid derivatives, antidepressants, adrenergic agonists, anticholinergics, anesthetics) without a washout of at least five biological half-lives before DaT-SPECT, per the EANM/SNMMI guidelines.
- DaT-SPECT performed outside the January 2015 - May 2025 period.
- Images not meeting the acquisition and quality specifications listed above.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: CASE_ONLY
- Prospettive temporali: RETROSPECTIVE
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
|---|---|
|
Adults referred for DaT-SPECT
Adults referred for evaluation of nigrostriatal dopaminergic dysfunction at the two participating centers between January 2015 and May 2025, whose existing 123I-ioflupane DaT-SPECT scans were selected retrospectively (30 per visual grade 0-3, 15 per grade per center). Each scan is read visually by four blinded readers, analyzed by DOlab software, and then re-read with the software report. |
Investigational software (not CE-marked, class IIa) that automatically quantifies striatal 123I-ioflupane binding using four metrics (SBR, Southampton SBR, Basal Ganglia V3, Volume Fraction) and compares them with a PPMI-based normative database. It is applied retrospectively to existing images, and its output is not used for patient care. Visual reading of the same 123I-ioflupane images by blinded nuclear medicine physicians, scored 0-3 for the caudate, anterior putamen and posterior putamen of each hemisphere, according to the EANM/SNMMI guidelines. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Correlation between visual score and DOlab quantitative metrics
Lasso di tempo: Phase 1 reading session, within 4 months of study start
|
Pearson correlation coefficient (with 95% CI) between the readers' visual score (ordinal 0-3; 0 = normal, 3 = marked abnormality) and each continuous metric produced by DOlab software (SBR, Southampton SBR, Basal Ganglia V3, Volume Fraction) for the caudate, anterior putamen and posterior putamen of each hemisphere. If the Pearson assumptions are not met, the Spearman rank correlation is reported. |
Phase 1 reading session, within 4 months of study start
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Agreement between visual and software-supported semi-quantitative classification
Lasso di tempo: Phase 2 reading session, within 4 months of study start
|
Cohen's kappa coefficient between the classifications given by the same readers with visual reading alone (Phase 1) and with the DOlab software report (Phase 2). |
Phase 2 reading session, within 4 months of study start
|
|
Number of scans reclassified with software support
Lasso di tempo: Phase 2 reading session, within 4 months of study start
|
Number and percentage of scans whose classification changes between visual reading alone and software-supported reading (e.g., borderline to abnormal), tested with McNemar's test for paired proportions. |
Phase 2 reading session, within 4 months of study start
|
|
Software usability (System Usability Scale)
Lasso di tempo: After the Phase 2 reading session, within 4 months of study start
|
SUS questionnaire completed by the 4 readers: 10 items on a 5-point scale. SUS total score from 0 to 100, where higher scores indicate better perceived usability; item responses are also reported as median and IQR. |
After the Phase 2 reading session, within 4 months of study start
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Stelvio Sestini, MD, Azienda USL Toscana Centro - Santo Stefano Hospital, Prato
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Sinucleinopatie
- Malattie del cervello
- Malattie del sistema nervoso centrale
- Malattie del sistema nervoso
- Disordini mentali
- Disturbi neurocognitivi
- Demenza
- Malattie Neurodegenerative
- Malattie dei gangli basali
- Disturbi del movimento
- Morbo di Parkinson
- Malattia del corpo di Lewy
- Malattie parkinsoniane
Altri numeri di identificazione dello studio
- Dorian-2025
- IT-26-01-056194 (Altro identificatore: EUDAMED (Italian Ministry of Health))
- 29262_spe (Altro identificatore: Comitato Etico Regione Toscana - Area Vasta Centro)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Individual participant data and images will not be shared, because the clinical investigation plan restricts data use to the sponsor and investigators and the dataset includes pseudonymized imaging data of patients who could not all be reconsented. Aggregate results will be published.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .